VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
-
B7-H3 in glioblastoma and beyond [Elektronski vir] : significance and therapeutic strategiesBabič, Davor, kemija ; Jovchevska, Ivana ; Zottel, AljaCancer has emerged as the second most prevalent disease and the leading cause of death, claiming the lives of 10 million individuals each year. The predominant varieties of cancer encompass breast, ... lung, colon, rectal, and prostate cancers. Among the more aggressive malignancies is glioblastoma, categorized as WHO stage 4 brain cancer. Following diagnosis, the typical life expectancy ranges from 12 to 15 months, as current established treatments like surgical intervention, radiotherapy, and chemotherapy using temozolomide exhibit limited effectiveness. Beyond conventional approaches, the exploration of immunotherapy for glioblastoma treatment is underway. A methodology involves CAR-T cells, monoclonal antibodies, ADCC and nanobodies sourced from camelids. Immunotherapy’s recent focal point is the cellular ligand B7-H3, notably abundant in tumor cells while either scarce or absent in normal ones. Its expression elevates with cancer progression and serves as a promising prognostic marker. In this article, we delve into the essence of B7-H3, elucidating its function and involvement in signaling pathways. We delineate the receptors it binds to and its significance in glioblastoma and other cancer types. Lastly, we examine its role in immunotherapy and the utilization of nanobodies in this domain.Vir: Frontiers in immunology [Elektronski vir]. - ISSN 1664-3224 (Vol. 15, iss [article no.] 1495283, Nov. 2024, str. 1-21)Vrsta gradiva - e-članek ; neleposlovje za odrasleLeto - 2024Jezik - angleškiCOBISS.SI-ID - 216635139
Digitalne vsebine: dCOBISS
| Avtor | Babič, Davor, kemija ; Jovchevska, Ivana ; Zottel, Alja |
| Naslov | B7-H3 in glioblastoma and beyond [Elektronski vir] : significance and therapeutic strategies |
| Datum objave | |
| COBISS.SI-ID | 216635139 |
| Verzija objave v repozitoriju | Založnikova različica |
| Licenca objave v repozitoriju | Creative Commons Priznanje avtorstva 4.0 Mednarodna |
| Embargo | Ni določeno |
Projekti in financerji, navedeni v objavi
| Naziv | Akronim | Številka projekta | Financer |
|---|---|---|---|
| Vpliv imunoterapije z anti-PD-L1 atezolizumabom in nanotelesom Nb202 na organoide glioblastoma pripravljene iz tkiva bolnikov | Z3-4510-2022 |
Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije |
|
| Funkcijska genomika in biotehnologija za zdravje | P1-0390-2022 |
Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije |
Datoteke, ki spadajo k objavi
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1495283/full
Vir: Osebne bibliografije
in: SICRIS
